MX2019008564A - Composiciones inmunogenicas para su uso en vacunas neumococicas. - Google Patents

Composiciones inmunogenicas para su uso en vacunas neumococicas.

Info

Publication number
MX2019008564A
MX2019008564A MX2019008564A MX2019008564A MX2019008564A MX 2019008564 A MX2019008564 A MX 2019008564A MX 2019008564 A MX2019008564 A MX 2019008564A MX 2019008564 A MX2019008564 A MX 2019008564A MX 2019008564 A MX2019008564 A MX 2019008564A
Authority
MX
Mexico
Prior art keywords
immunogenic compositions
pneumococcal vaccines
pneumococcal
present
pneumoniae
Prior art date
Application number
MX2019008564A
Other languages
English (en)
Other versions
MX392525B (es
Inventor
Ute Jansen Kathrin
William Pride Michael
Cooper David
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2019008564A publication Critical patent/MX2019008564A/es
Publication of MX392525B publication Critical patent/MX392525B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un objeto de la presente invención es proporcionar composiciones inmunogénicas para protección contra S.pneumoniae, en particular contra El grupo sérico 18 de S. pneumoniae, mientras que limita el número de conjugados. La presente invención por lo tanto se relaciona con composiciones inmunogénicas novedosas para su uso en vacunas neumocócicas y en vacunación de sujetos humanos, en particular lactantes y personas mayores, contra infecciones neumocócicas utilizando las composiciones inmunogénicas.
MX2019008564A 2017-01-20 2018-01-05 Composiciones inmunogenicas para su uso en vacunas neumococicas MX392525B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762448485P 2017-01-20 2017-01-20
PCT/IB2018/050084 WO2018134693A1 (en) 2017-01-20 2018-01-05 Immunogenic compositions for use in pneumococcal vaccines

Publications (2)

Publication Number Publication Date
MX2019008564A true MX2019008564A (es) 2019-09-19
MX392525B MX392525B (es) 2025-03-12

Family

ID=61028107

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008564A MX392525B (es) 2017-01-20 2018-01-05 Composiciones inmunogenicas para su uso en vacunas neumococicas

Country Status (17)

Country Link
US (2) US11413344B2 (es)
EP (1) EP3570879B1 (es)
JP (1) JP7120767B2 (es)
KR (1) KR102459629B1 (es)
CN (1) CN110198735A (es)
AU (1) AU2018208844B2 (es)
BR (1) BR112019014833A2 (es)
DK (1) DK3570879T3 (es)
ES (1) ES2911490T3 (es)
HR (1) HRP20220573T1 (es)
HU (1) HUE059252T2 (es)
IL (1) IL268168A (es)
MX (1) MX392525B (es)
PL (1) PL3570879T3 (es)
RU (1) RU2762723C2 (es)
SI (1) SI3570879T1 (es)
WO (1) WO2018134693A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3096783B1 (en) 2014-01-21 2021-07-07 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
IL303998A (en) * 2015-07-21 2023-08-01 Pfizer Immunogenic preparations containing conjugated capsular sugar antigens, kits containing them and their uses
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
US11998599B2 (en) 2016-12-30 2024-06-04 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
RU2762723C2 (ru) 2017-01-20 2021-12-22 Пфайзер Инк. Иммуногенные композиции для применения в пневмококковых вакцинах
CN110225764A (zh) 2017-01-31 2019-09-10 默沙东公司 制备多糖-蛋白缀合物的方法
CA3050120A1 (en) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
KR102734995B1 (ko) 2017-09-07 2024-11-26 머크 샤프 앤드 돔 엘엘씨 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
KR102736151B1 (ko) 2017-09-07 2024-11-28 머크 샤프 앤드 돔 엘엘씨 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
UA128603C2 (uk) 2017-12-06 2024-08-28 Мерк Шарп Енд Доум Елелсі Полівалентна імуногенна композиція проти пневмококового захворювання
JP7397000B2 (ja) 2018-04-30 2023-12-12 メルク・シャープ・アンド・ドーム・エルエルシー 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法
CN112074294B (zh) 2018-04-30 2025-07-11 默沙东有限责任公司 从冻干球生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法
CN120661645A (zh) 2018-04-30 2025-09-19 默沙东有限责任公司 生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法
SG11202106541WA (en) 2018-12-19 2021-07-29 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
EP4212178A1 (en) 2020-09-10 2023-07-19 United Immunity, Co., Ltd. Complex
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
EP0911036A3 (en) 1992-02-11 2001-05-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
EP0643559B1 (en) 1992-05-06 1999-04-14 The President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
ES2210262T3 (es) 1993-09-22 2004-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
ATE241384T1 (de) 1995-03-22 2003-06-15 Jackson H M Found Military Med Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
DE69935507T2 (de) 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
CN101926993B (zh) 1998-10-16 2013-12-04 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
PT1140157E (pt) 1998-12-21 2009-05-06 Medimmune Inc Proteínas de streptococcus pneumoniae e fragmentos imunogénicos para vacinas
CN100398653C (zh) 1998-12-23 2008-07-02 益得生物医学公司 新颖的链球菌抗原
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
DK2204186T3 (en) 1999-02-17 2016-07-18 Csl Ltd Immunogenic complexes, and related methods
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
WO2000056359A2 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against streptococcus pneumoniae
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
PL203951B1 (pl) 1999-04-19 2009-11-30 Smithkline Beecham Biolog Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie
WO2001021207A2 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
CA2413450C (en) 2000-06-20 2014-02-18 Shire Biochem Inc. Streptococcus antigens
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
US8084235B2 (en) 2003-03-13 2011-12-27 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
WO2004083251A2 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CA2574090A1 (en) 2004-07-18 2006-12-21 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
EP2484374A1 (en) 2004-07-18 2012-08-08 CSL Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN113198012B (zh) * 2005-04-08 2024-09-17 惠氏有限责任公司 多价肺炎球菌多糖－蛋白质缀合物组合物
JP5049264B2 (ja) 2005-04-08 2012-10-17 ワイス・エルエルシー ｐＨ操作によるストレプトコッカス・ニューモニエ多糖からの混入物の分離
CA2808919C (en) * 2005-12-22 2016-04-19 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae capsular saccharide vaccine
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
KR101467002B1 (ko) 2006-10-10 2014-12-01 와이어쓰 엘엘씨 스트렙토코쿠스 뉴모니애 제3형 다당류의 정제 방법
SI2436700T1 (sl) 2007-03-23 2018-09-28 Wyeth Llc Skrajšan postopek čiščenja za proizvodnjo kapsularnih polisaharidov streptococcusa pneumoniae
KR101579947B1 (ko) 2007-06-26 2015-12-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
US20120064103A1 (en) * 2009-03-24 2012-03-15 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
EP2424562B1 (en) 2009-04-30 2015-10-07 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
CA2803061A1 (en) * 2009-06-29 2011-01-20 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae
CN102068690A (zh) * 2010-12-31 2011-05-25 北京民海生物科技有限公司 多价肺炎球菌荚膜多糖结合疫苗及其制备方法
PL2885007T3 (pl) 2012-08-16 2019-02-28 Pfizer Inc. Sposoby glikokoniugacji i kompozycje
KR101787217B1 (ko) 2012-12-20 2017-10-18 화이자 인코포레이티드 당접합 방법
CN103495161B (zh) 2013-10-08 2019-06-18 江苏康泰生物医学技术有限公司 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法
SI3583947T1 (sl) * 2014-01-21 2024-01-31 Pfizer Inc. Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
KR102157200B1 (ko) * 2014-01-21 2020-09-21 화이자 인코포레이티드 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
CN104069504B (zh) 2014-05-11 2019-09-24 江苏康泰生物医学技术有限公司 一种增强多糖蛋白结合物免疫原性的方法
IL252915B2 (en) * 2015-01-15 2024-04-01 Pfizer Immunogenic compositions for use in pneumococcal vaccines
RU2762723C2 (ru) 2017-01-20 2021-12-22 Пфайзер Инк. Иммуногенные композиции для применения в пневмококковых вакцинах

Also Published As

Publication number Publication date
DK3570879T3 (da) 2022-04-11
SI3570879T1 (sl) 2022-06-30
RU2019122619A (ru) 2021-02-20
WO2018134693A1 (en) 2018-07-26
CA3050622A1 (en) 2018-07-26
AU2018208844A1 (en) 2019-07-11
JP2018115159A (ja) 2018-07-26
ES2911490T3 (es) 2022-05-19
US20190343946A1 (en) 2019-11-14
KR102459629B1 (ko) 2022-10-28
RU2019122619A3 (es) 2021-02-20
US12318438B2 (en) 2025-06-03
RU2762723C2 (ru) 2021-12-22
PL3570879T3 (pl) 2022-06-20
IL268168A (en) 2019-09-26
KR20190097176A (ko) 2019-08-20
EP3570879A1 (en) 2019-11-27
US20230190907A1 (en) 2023-06-22
CN110198735A (zh) 2019-09-03
MX392525B (es) 2025-03-12
EP3570879B1 (en) 2022-03-30
JP7120767B2 (ja) 2022-08-17
HRP20220573T1 (hr) 2022-06-10
HUE059252T2 (hu) 2022-11-28
BR112019014833A2 (pt) 2020-04-14
US11413344B2 (en) 2022-08-16
AU2018208844B2 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
MX2019008564A (es) Composiciones inmunogenicas para su uso en vacunas neumococicas.
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
MX2021000523A (es) Composiciones inmunogenicas que comprenden antigenos sacaridos capsulares conjugados y usos de los mismos.
CO2018000503A2 (es) Composiciones inmunógenas que comprenden antígenos de sacárido capsular conjugados, kits que las comprenden y sus usos
CL2018000319A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
MX2022002106A (es) Formulaciones de vacuna de vial unico.
MX2025002465A (es) Metodos y dispositivos para la preparacion de agentes de contraste de ultrasonido
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
BR112014020025A2 (pt) vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
CL2016000787A1 (es) Composición farmacéutica en forma de comprimido que comprende atazanavir y cobicistat; procedimiento de preparación; y uso de la composición para preparar un medicamento útil para tratar la infección por el virus de inmunodeficiencia humana (vih).
MX2019002552A (es) Composicion que comprende polisacarido capsular neumococico multivalente-proteina transportadora y uso de la misma.
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
MX2023005221A (es) Composiciones inmunogenicas para uso en vacunas neumococicas.
BR112022002094A2 (pt) Composição imunogênica
MX388528B (es) Vacuna que comprende toxoides de clostridium.
AR095501A1 (es) Vacunas rsv